Biopharmaceutical Manufacturing Market Report by Cell Culture (Mammalian Cell Culture, Microbial Cell Culture), Class (Monoclonal Antibodies, Recombinant Proteins, Interferon, Granulocyte Colony-Stimulating Factor (G-CSF), Erythropoietin, Recombinant Human Insulin, Vaccines, Human Growth Hormones (HGH)), and Region 2024-2032

Biopharmaceutical Manufacturing Market Report by Cell Culture (Mammalian Cell Culture, Microbial Cell Culture), Class (Monoclonal Antibodies, Recombinant Proteins, Interferon, Granulocyte Colony-Stimulating Factor (G-CSF), Erythropoietin, Recombinant Human Insulin, Vaccines, Human Growth Hormones (HGH)), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A724
Buy Now

Market Overview:

The global biopharmaceutical manufacturing market size reached US$ 411.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 935.0 Billion by 2032, exhibiting a growth rate (CAGR) of 9.3% during 2024-2032. The growing adoption of biologics, innovations in biotechnology and genetic engineering techniques, and increasing incidences of several chronic diseases, such as cancer, autoimmune disorders, and diabetes, are some of the major factors propelling the market.

Report Attribute
 Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023
US$ 411.8 Billion
Market Forecast in 2032
US$ 935.0 Billion
Market Growth Rate 2024-2032
9.3%


Biopharmaceutical manufacturing is the process of producing medical drugs and therapies using living organisms or biological systems. It comprises the utilization of biotechnology, such as cell cultures and genetic engineering, to develop a wide range of pharmaceutical products. It involves multiple stages, including fermentation, cell culture, purification, and formulation, which require stringent quality control and regulatory compliance. It differs from traditional chemical-based methods, as it focuses on producing complex molecules, such as proteins, antibodies, and vaccines. As it provides innovative treatments for various medical conditions, the demand for biopharmaceutical manufacturing is rising across the globe.

Global Biopharmaceutical Manufacturing Market

At present, the increasing demand for efficient production processes and the adoption of single-use technologies to optimize manufacturing efficiency is influencing the market positively. Moreover, the rising awareness about the importance of biopharmaceuticals in improving healthcare outcomes is strengthening the growth of the market. Apart from this, the growing demand for biosimilars that are highly similar versions of approved biologics and are cost-effective alternatives while maintaining comparable efficacy and safety profiles is offering a favorable market outlook. Additionally, the rising preference for automation to streamline production, reduce human error, and enhance efficiency is offering lucrative growth opportunities to industry investors. Besides this, favorable government initiatives to promote healthcare infrastructure, which is impelling the growth of the market. In addition, the rising demand for advanced biopharmaceutical treatments among the masses worldwide is contributing to the growth of the market.

Biopharmaceutical Manufacturing Market Trends/Drivers:

Rising prevalence of chronic diseases

The rising incidence of several chronic diseases, such as cancer, autoimmune disorders, and diabetes, among the masses across the globe is contributing to the growth of the market. In line with this, there is an increase in the demand for targeted and personalized treatment options among individuals. Moreover, biopharmaceuticals offer precise targeting and fewer side effects as compared to traditional drugs. Apart from this, the rising development and manufacturing of biologics that address specific disease pathways and patient profiles is bolstering the growth of the market. Manufacturers are rapidly advancing their technologies to cater to the rising need for tailored therapies. As a result, healthcare systems are focusing on providing more effective and patient-centric treatment solutions.

Increasing adoption of biologics

The rising popularity of biologics, such as monoclonal antibodies, vaccines, and recombinant proteins due to their high specificity and efficacy in treating various diseases is supporting the growth of the market. Apart from this, they often provide targeted treatment with fewer adverse effects, which makes them a preferred choice among patients and healthcare professionals. In line with this, the growing demand for biopharmaceutical manufacturing due to the rising preference for biologics over traditional small molecule drugs is offering a favorable market outlook. Furthermore, companies are investing in expanding their biomanufacturing capabilities to meet the production needs of these complex therapeutic agents.

Innovations in biotechnology and genetic engineering techniques

Continuous advancements in biotechnology, such as genetic engineering and cell culture techniques, assist in the efficient production of biopharmaceuticals. Innovations in gene editing, protein expression, and cell line development significantly improved the efficiency and yield of biologics manufacturing. In addition, these advancements enable the creation of more complex and diverse biopharmaceutical products, ranging from monoclonal antibodies to gene therapies. Furthermore, innovations in high-throughput screening techniques assist in streamlining the identification of optimal production conditions. Moreover, the integration of synthetic biology principles enables the engineering of cellular pathways to enhance yield and product quality, which is offering a positive market outlook. These innovations not only enhance bioprocess development but also contribute to the production of tailored therapies.

Biopharmaceutical Manufacturing Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global biopharmaceutical manufacturing market report, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on cell culture and class.

Breakup by Cell Culture:

  • Mammalian Cell Culture
  • Microbial Cell Culture
     

Mammalian cell culture represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the cell culture. This includes mammalian cell culture and microbial cell culture. According to the report, mammalian cell culture represented the largest segment. Mammalian cell culture involves the cultivation of cells derived from mammals, such as humans or animals, in a controlled environment outside their natural habitat. This process serves as a foundation to produce biopharmaceuticals, such as monoclonal antibodies, vaccines, and recombinant proteins. It offers various advantages in terms of its ability to correctly fold and modify complex therapeutic proteins and closely represent human biology. In addition, biopharmaceutical manufacturing relies on advancements in mammalian cell culture techniques, which include optimizing culture media, bioreactor systems, and cell line development. The rising demand for mammalian cell culture due to the increasing need for innovative therapies is propelling the growth of the market.

Breakup by Class:

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Interferon
  • Granulocyte Colony-Stimulating Factor (G-CSF)
  • Erythropoietin
  • Recombinant Human Insulin
  • Vaccines
  • Human Growth Hormones (HGH)
     

Monoclonal antibodies account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the class. This includes monoclonal antibodies, recombinant proteins, interferon, granulocyte colony-stimulating factor (G-CSF), erythropoietin, recombinant human insulin, vaccines, and human growth hormones (HGH). According to the report, monoclonal antibodies represented the largest segment. Monoclonal antibodies are a class of biopharmaceuticals that are designed to target specific proteins or cells in the body. They are produced by cloning a single type of immune cell to create identical copies that generate uniform antibodies. mAbs gained popularity due to their precision in treating various diseases, such as cancer, autoimmune disorders, and infectious diseases. They offer high specificity, reduced side effects, and the ability to modulate the immune response. Apart from this, the rising need for personalized medicine is contributing to the growth of the market. Pharmaceutical companies invest in optimizing biopharmaceutical manufacturing processes to produce these complex molecules at commercial scales.

Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
     

North America exhibits a clear dominance, accounting for the largest biopharmaceutical manufacturing market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, and Asia Pacific. According to the report, North America accounted for the largest market share.

North America held the biggest market share on account of the improved healthcare infrastructure. In line with this, the rising innovation in pharmaceuticals is bolstering the growth of the market in the region. Moreover, the presence of major pharmaceutical companies and academic research institutions in the region is supporting the growth of the market. Apart from this, favorable regulatory frameworks are contributing to the growth of the market in the region.

Competitive Landscape:

Major players are investing in research and development (R&D) activities to discover and develop new biologic therapies. They are focusing on identifying novel targets, engineering efficient production processes, and enhancing the therapeutic properties of existing drugs. In line with this, companies are working to optimize cell culture, purification, and formulation techniques to increase production efficiency, reduce costs, and ensure consistent product quality. Apart from this, key manufacturers are implementing rigorous quality control measures and adhering to regulatory guidelines to meet stringent manufacturing and validation requirements. Furthermore, companies are investing in expanding production facilities and adopting advanced technologies to accommodate larger volumes.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.

Recent Developments:

  • In 2022, Johnson & Johnson and its China-focused partner Legend Biotech Corp (LEGN.O) got the approval from U.S. Food and Drug Administration (FDA) for CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy.
  • In January 2022, Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.
  • In 2021, Sanofi announced an agreement to acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company leveraging its proprietary, clinically validated XTEN® and innovative universal protease-releasable masking technology platform, Pro-XTENTM, to discover and develop transformative T-cell engagers (TCE) and cytokine therapies for patients with cancer.

Biopharmaceutical Manufacturing Market Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units Kilo Liters
Scope of the Report Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
  • Cell Culture 
  • Class 
  • Region
Cell Cultures Covered Mammalian Cell Culture, Microbial Cell Culture
Classes Covered Monoclonal Antibodies, Recombinant Proteins, Interferon, Granulocyte Colony-Stimulating Factor (G-CSF), Erythropoietin, Recombinant Human Insulin, Vaccines, Human Growth Hormones (HGH)
Regions Covered Asia Pacific, Europe, North America
Companies Covered AbbVie Inc., Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Benefits for Stakeholders:

  • IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the biopharmaceutical manufacturing market from 2018-2032.
  • The research report study provides the latest information on the market drivers, challenges, and opportunities in the global biopharmaceutical manufacturing market.
  • The study maps the leading, as well as the fastest-growing, regional markets.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the biopharmaceutical manufacturing industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Key Questions Answered in This Report

The global biopharmaceutical manufacturing market was valued at US$ 411.8 Billion in 2023.

We expect the global biopharmaceutical manufacturing market to exhibit a CAGR of 9.3% during 2024-2032.

The rising demand for biopharmaceutical manufacturing in providing innovative and effective treatments for various diseases, such as cancer, autoimmune disorders, and genetic conditions, is primarily driving the global biopharmaceutical manufacturing market.

The sudden outbreak of the COVID-19 pandemic has led to the increasing adoption of biopharmaceutical manufacturing in producing medical drugs and therapies for the treatment of the coronavirus-infection.

Based on the cell culture, the global biopharmaceutical manufacturing market has been segmented into mammalian cell culture and microbial cell culture, where mammalian cell culture currently holds the majority of the total market share.

Based on the class, the global biopharmaceutical manufacturing market can be divided into monoclonal antibodies, recombinant proteins, interferon, Granulocyte Colony-Stimulating factor (G-CSF), erythropoietin, recombinant human insulin, vaccines, and Human Growth Hormones (HGH). Currently, monoclonal antibodies exhibit a clear dominance in the market.

On a regional level, the market has been classified into North America, Europe, and Asia Pacific, where North America currently dominates the global market.

Some of the major players in the global biopharmaceutical manufacturing market include AbbVie Inc., Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., etc.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Biopharmaceutical Manufacturing Market Report by Cell Culture (Mammalian Cell Culture, Microbial Cell Culture), Class (Monoclonal Antibodies, Recombinant Proteins, Interferon, Granulocyte Colony-Stimulating Factor (G-CSF), Erythropoietin, Recombinant Human Insulin, Vaccines, Human Growth Hormones (HGH)), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More